✦ LIBER ✦

32 A PHASE 1, MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-ESCALATION STUDY OF IMO-2125, A TLR9 AGONIST, IN HEPATITIS C-NONRESPONDERS

✍ Scribed by A. Muir; R. Ghalib; E. Lawitz; K. Patel; M. Rodriguez-Torres; A. Sheikh; S. Sapp; R. Taylor; A. Bexon; T. Sullivan; A. Dovholuk; J. Mc Hutchison

Book ID: 117378120
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 53 KB
Volume: 52
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(10)60034-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

300 PHASE 1B DOSE-ESCALATION STUDY OF SD

300 PHASE 1B DOSE-ESCALATION STUDY OF SD-101, A NOVEL THERAPEUTIC TLR-9 AGONIST, IN TREATMENT-NAIVE CHRONIC HEPATITIS C PATIENTS

✍ J. Cianciara; J.T. Martin; M.C. Spellman 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 95 KB

111 Final results of a multi-center phas

111 Final results of a multi-center phase 1b, randomized, placebo-controlled, doseescalation trial of CPG 10101 in patients with chronic hepatitis C virus

✍ J.G. McHutchison; B.R. Bacon; S.C. Gordon; E. Lawitz; M. Shiffman; N.H. Afdhal; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 94 KB

A phase 1, randomized, placebo-controlle

A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C

✍ Eric J. Lawitz; Daniel Gruener; John M. Hill; Thomas Marbury; Lisa Moorehead; An 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 830 KB

46 A Phase 2a Randomized Placebo-Control

46 A Phase 2a Randomized Placebo-Controlled Double-Blind Multi-Center Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AG011 in Patients With Moderately Active Ulcerative Colitis

✍ Severine Vermeire; Paul J. Rutgeerts; Geert R. D'Haens; Martine De Vos; Brian Br 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 47 KB

1188 PHASE 2 RANDOMIZED, DOUBLE-BLIND, P

1188 PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF NITAZOXANIDE WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN NONRESPONDERS (NR) WITH CHRONIC HEPATITIS C GENOTYPE 1: FINAL REPORT

✍ Shiffman, M.L.; Ahmed, A.; Jacobson, I.M.; Pruitt, R.E.; Keeffe, E.B. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 55 KB

Sa1319 A Phase II, Randomized, Placebo-C

Sa1319 A Phase II, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study to Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis (S-USIIT-01)

✍ Hassanein, Tarek; Box, Terry D.; Tong, Myron J.; Pozza, Renee; Rossaro, Lorenzo; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 94 KB